XML 91 R58.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue and Geographic Area - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Apr. 30, 2024
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Mar. 31, 2024
Jan. 31, 2022
Mar. 31, 2020
Disaggregation of Revenue [Line Items]                  
Total revenue       $ 174,432 $ 106,340 $ 97,948      
Purchase to equipment supplies and training       8,355 2,831 3,825      
Transaction price [1]       16,603          
Deferred revenue     $ 17,913 45,792 15,127 14,608      
Research and development services       62,411 25,948 37,382      
Illumina Cambridge, Ltd.                  
Disaggregation of Revenue [Line Items]                  
Non-refundable upfront payment               $ 30,000  
Purchase to equipment supplies and training     500            
Transaction price     30,400       $ 400    
Revenue receive minimum guaranteed royaltie     124,500            
Transaction price royalties expected to be received             8 years    
Deferred revenue     0 $ 30,012 0 0      
Illumina Cambridge, Ltd. | Minimum                  
Disaggregation of Revenue [Line Items]                  
Transaction price royalties expected to be received             2025 years    
Illumina Cambridge, Ltd. | Maximum                  
Disaggregation of Revenue [Line Items]                  
Transaction price royalties expected to be received             2032 years    
Illumina Cambridge, Ltd. | Illumina Agreement                  
Disaggregation of Revenue [Line Items]                  
Transaction price     30,500       $ 158,400    
Transaction price royalties expected to be received       8 years          
Illumina Cambridge, Ltd. | Royalties                  
Disaggregation of Revenue [Line Items]                  
Transaction price             $ 127,900    
NEC                  
Disaggregation of Revenue [Line Items]                  
Deferred revenue     $ 0 $ 763 $ 0 $ 0     $ 1,800
Research and development services $ 2,000                
New England Biolabs, Inc.                  
Disaggregation of Revenue [Line Items]                  
Revenue receive minimum guaranteed royaltie   $ 5,000              
License agreement related royalties receivable       $ 4,700          
Soma Logic Plans                  
Disaggregation of Revenue [Line Items]                  
Revenue receive minimum guaranteed royaltie   $ 0              
Revenue from Contract with Customer | Customer Concentration Risk | One Genomics Customer                  
Disaggregation of Revenue [Line Items]                  
Concentration risk, percentage       6.00% 10.00% 11.00%      
Revenue from Contract with Customer | Customer Concentration Risk | Five Largest Customers                  
Disaggregation of Revenue [Line Items]                  
Concentration risk, percentage       22.00% 24.00% 19.00%      
Accounts Receivable | Customer Concentration Risk | Customer One                  
Disaggregation of Revenue [Line Items]                  
Concentration risk, percentage       5.00% 14.00%        
United States | Revenue from Contract with Customer | Geographic Concentration Risk                  
Disaggregation of Revenue [Line Items]                  
Total revenue       $ 89,900 $ 44,100 $ 41,000      
Concentration risk, percentage       52.00% 41.00% 42.00%      
China | Revenue from Contract with Customer | Geographic Concentration Risk                  
Disaggregation of Revenue [Line Items]                  
Total revenue       $ 11,800          
Concentration risk, percentage       7.00% 15.00% 11.00%      
[1] Expected revenue includes both billed amounts included in deferred revenue and unbilled amounts that are not reflected in the Company's consolidated financial statements and are subject to change if the Company's customers decide to cancel or modify their contracts. Purchase orders for instrument service contracts can generally be canceled before the service period begins.